Discussion and conclusion
BCG, an attenuated form of
M. bovis, is the only vaccination approved to apply to clinic. WHO recommends BCG vaccinates newborns to prevent from miliary and meningeal forms of TB in high TB burden countries. Some primary immunodeficiency diseases (PIDs) make patients vulnerable to weakly virulent pathogens, including BCG, although BCG has good safety. Hence, some children suffering from PIDs developed regional disease (BCG-itis) or disseminated disease (BCG-osis) after vaccinating BCG [
4]. BCG-osis usually cause distant lymph nodes, liver and spleen enlargement, bone also involved. BCG-itis is characterized as purulent regional lymphadenitis, local erythema accompanied by ipsilateral regional lymph node enlargement. Hence, the diagnosis of them is based on the history of BCG vaccination, clinical, laboratory and imaging characters [
5]. Differ from BCG-osis, BCG-itis may not require anti-tuberculosis therapy.
One week after first visiting our outpatient, we got the result of T-SPOT, smear, Gene-Xpert and PCR of the aspirated material, and based on chest CT, brain MRI, BCG-itis was strongly suspected, we offer immunomodulator therapy instead of anti-tuberculosis. A few weeks later, the result of culture and bacteria identification confirmed our diagnosis.
NPC is commonly considered as a neurovisceral disease [
6], and mainly manifest as a progressive neurodegenerative disorder, consisting of cerebellar ataxia, seizures, progressive dementia, vertical supranuclear gaze palsy, dysarthria and dysphagia, and neonatal cholestatic jaundice, hepatosplenomegaly [
2] and recurrent respiratory infections [
7] are other common features. Each manifestation follows independent courses and occurs at different times. Systemic disease may be absent in 15 % patients [
8], always precedes neurological symptoms. Another clinical feature is the age of onset ranging from the perinatal period to more than 70 years old [
6]. The diagnosis of NPC is according to laboratory test——the skin fibroblasts demonstrate the impaired ability to transport intracellular cholesterol [
8]. Miglustat has been approved for NPC by the European Union, which can postpone disease progress in late-onset and not too advanced patients, especially patients who are at late-onset of disease [
6]. NPC1 of the patient is diagnosed based on twice gene testing results and the clinical presentation of splenomegaly. And Miglustat was used to treat NPC1 under the guidance of a specialist as soon as diagnosed.
The main transport pathway of intracellular cholesterol can be described simply as following: Low-density lipoprotein (LDL) recognizes, aggregates and binds to the LDL receptor on the cell membrane, then enters cells via endocytosis. After endosome fuses with the lysosome, the cholesterol ester is disassembled into free UC. The protein NPC2, a soluble, cholesterol-binding luminal protein in the lumen, transfers cholesterol to the N-terminal domain of NPC 1, a transmembrane glycoprotein in the LE/LY. Then, the protein NPC1 transfers UC to organelle (e.g. ER) [
2,
9]. That is a crucial pathway of intracellular cholesterol trafficking. However, the mutation of lysosomal integral membrane protein NPC1 [
10] makes lips cannot be transferred by the protein NPC1 and UC, glycosphingolipids, sphingomyelin, and sphingosine accumulating in cells [
1]. Moreover, cholesterol is a beneficial factor of
Mtb intracellular existing persistently. Taken together, it is reasonable to believe that NPC cells are beneficial for
Mtb survival.
The immune response, critical for control of
Mtb infection in humans, starts with macrophages. After infection, macrophages phagocytize
Mtb and become phagosomes to fused with lysosomes, then form phagolysosomes. The acid hydrolase in lysosomes kills
Mtb or inhibits its growth (phagosome acidification). Macrophages can also kill
Mtb by generating free radicals, autophagy, and initiating adaptive immune responses as antigen-presenting cells [
11]. Studies have shown that the phagocytosis of macrophages and the long-term survival of intracellular
Mtb depend on cholesterol. Accumulation of cholesterol is not only utilized by
Mtb as a source of carbon for survival but also decreases the PH of lysosome to support the survival of
Mtb [
12,
13]. Moreover, it is a consistent and prominent feature that lipid-laden macrophages appear in both granulomatous lesions and
Mtb infectious lesions [
14]. It can be speculated that the bactericidal activity of NPC cells decreases and the viability of intracellular
Mtb increases. NK cells are also involved in innate immunity. NK cells inhibit
Mtb growth directly via cytotoxic mechanisms and indirectly via immune-stimulating macrophages active [
11]. A study of a mouse model found that NPC1
−/− mouse is deficient in the peripheral immune system, especially NK cells. The frequency of NK cells decreases in circulation and the function is weaker [
10]. NKT cells were also revealed involved in response to
Mtb infection [
15], and iNKT cell control of
Mtb growth was CD1d-dependent [
16], which presented lipid antigens. The NPC cells might affect the antigen presentation pathway, and restrict iNKT cell effector function during infection.
As mentioned above, phagosome acidification is one mechanism of anti-tuberculosis innate immunity. In 2012, research demonstrated that all-trans retinoic acid (ATRA)-induced cellular antimicrobial activity depended on the expression and function of the protein NPC2. In detail, ATRA induces the protein NPC2 expressing to decrease intracellular cholesterol and increase in lysosome acidification. Conversely, ATRA-induced antimicrobial activity can be ablated because of the loss of the protein NPC2 [
13]. In the cholesterol transport pathway, the protein NPC1 locates downstream of the protein NPC2, and both of them play a role in transporting UC. Taken together, it is reasonable to speculate that the non-expression of NPC1 can cause a decrease in lysosomal acidification, which affects a key process in antimicrobial activity against
Mtb of innate immunity.
LDL can also be oxidized to oxidized LDL (oxLDL) which can be phagocytized by macrophages and vascular endothelial cells. It has been demonstrated that lysosomal cholesterol esterase cannot disassemble oxLDL-derived lipids, which leads to lipid accumulation in lysosomes in macrophages, and dysfunction in intracellular cholesterol transportation and effluxion [
12]. This is similar to what happens in NPC cells. Another experiment showed that cholesterol accumulation due to oxLDL uptake or NPC1 deficiency results in lysosomal dysfunction in macrophages by interfering with phagolysosomes trafficking, maturation, and fusion; inhibiting autophagy; increasing the PH of lysosomal; damaging the lysosomal membrane directly and triggering downstream inflammatory [
12], which is beneficial for the growth of
Mtb, as some mechanisms consistent with immune evasion mechanism of
Mtb.
Besides, a study indicates that foamy macrophages containing oxLDL, appearing during TB development, support
Mtb survival because of intracellular cholesterol accumulation, which is considered significant for the development of tuberculous granulomas and persistence of
Mtb infection [
12].
Besides, a study indicated that the phenotype of cells infected with
M. bovis BCG and wild-type Mtb is consistent with NPC cells [
17], and the protein NPC1 can regulate liver X receptor (LXR)-dependent cholesterol efflux and relieve cholesterol-induced oxidative stress in macrophages [
9]. Based on that, it is reasonable speculation that the protein NPC1 is an effective factor to reduce the viability and even prevent infection of
M. bovis BCG and
Mtb.
The live attenuated vaccine BCG is safe for the general population but risky in patients with PIDs, especially for those with BCG-osis. As NPC1 is a rare gene deficiency disease, there is no evident result linking NPC1 with BCG-itis. However, there is a lot of evidence relating NPC1 with
Mtb that NPC cells are beneficial for
Mtb infection and intracellular survival. Moreover, Crohn’s disease has been reported in association with NPC, Schwerd et al. [
18] demonstrated that NPC1 mutations in vitro induce a defect in autophagy which leads to impaired NOD2-mediated bacterial killing by macrophages. In summary, we can reasonably speculate that NPC1 is a susceptibility gene of
Mtb infection and mainly affects innate immunity. Therefore, mutation of NPC1 may cause adverse reactions after BCG vaccination, but it tends to result in BCG-itis. NPC1 is an autosomal recessive disorder, the clinical symptoms appear when the gene is homozygous (NPC1
−/−). Therefore, it is recommended that genetic counseling in patients with NPC1 in the family, antenatal tests (e.g. amniocentesis) to clarify whether there is a defect in the NPC1 gene. Once diagnosed, the infant should not be vaccinated with BCG and early treated. But in order to determine the relationship between NPC1 with
M. bovis BCG, it is necessary to experiment in animals and search for more NPC1 patients with BCG-itis.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.